Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Increased risks of lymphoma and infections are known risks associated with DMARDs, and the incidence of these adverse effects as reported in the studies was reviewed.
Other adverse effects of interest include mortality, hepatitis, bone marrow suppression, nausea or vomiting, and risks to the fetus or pregnant mother.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.